Dr. Mark M. Gitau, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 220
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
ND license 11318 -
Hematology & Oncology Physician
MN license 53892
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sanford Medical Center Fargo Fargo, ND
- Perham Health Perham, MN
- Sanford Thief River Falls Medical Center Thief River Falls, MN
- Jamestown Regional Medical Center Jamestown, ND
- Sanford Wheaton Medical Center Wheaton, MN
Medical groups
- Sanford Medical Center Fargo (1,225 clinicians)
- Sanford Health Network North (116 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 220
- Services billed
- 1,442
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 317 | 171 |
| Established patient office or other outpatient visit, 40-54 minutes | 74 | 51 |
| Established patient office or other outpatient visit, 20-29 minutes | 24 | 21 |
| New patient office or other outpatient visit, 60-74 minutes | 20 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Fargo, ND | 149 |
| Letrozole Other prescribers in Fargo, ND | 85 |
| Dexamethasone Other prescribers in Fargo, ND | 32 |
| Prochlorperazine Maleate Other prescribers in Fargo, ND | 27 |
| Prednisone Other prescribers in Fargo, ND | 23 |
| Gabapentin Other prescribers in Fargo, ND | 22 |
| Eliquis (apixaban) Other prescribers in Fargo, ND | 21 |
| Hydroxyurea Other prescribers in Fargo, ND | 17 |
| Ondansetron Hcl Other prescribers in Fargo, ND | 16 |
| Verzenio (abemaciclib) | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $181,691 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB N2 NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platin…
Merck Sharp & Dohme LLC - A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants with EGFR-mutated, Advanced Non-squamous Non-small Cell Lung Cancer NSCLC Who Have Progressed on Prior EGFR Tyrosine Kinase Inhi…
Merck Sharp & Dohme LLC - A Phase 3 Clinical Trial of Pembrolizumab MK-3475 in First Line Treatment of Recurrent,Metastatic Head and Neck Squamous Cell Carcinoma
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.